Cervical cancer remains a significant global health challenge, particularly in less developed regions, despite advancements in prevention and treatment. The World Health Organization (WHO) has prioritized vaccination as a key strategy for cervical cancer elimination. However, limited vaccine coverage persists, especially in countries like India and China. In India, cervical cancer is a leading cause of female mortality, highlighting the urgent need for population-based interventions. Human papillomavirus (HPV) is the primary causative agent, with HPV-16 and 18 being prevalent in Indian women. Since its recommendation in 2006, the HPV vaccine has shown remarkable efficacy, with the potential to prevent over 90% of HPV-attributable cancers. Recent advancements include the development of single-dose vaccines, offering a cost-effective solution to enhance accessibility. Democratizing access to vaccines is crucial for achieving WHO's goals of cervical cancer elimination.